摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tetraethyl 9-oxoheptadecane-1,8,10,17-tetracarboxylate | 1443113-94-7

中文名称
——
中文别名
——
英文名称
tetraethyl 9-oxoheptadecane-1,8,10,17-tetracarboxylate
英文别名
Tetraethyl 9-oxoheptadecane-1,8,10,17-tetracarboxylate
tetraethyl 9-oxoheptadecane-1,8,10,17-tetracarboxylate化学式
CAS
1443113-94-7
化学式
C29H50O9
mdl
——
分子量
542.711
InChiKey
XREWRQYSHWKVDR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.9
  • 重原子数:
    38
  • 可旋转键数:
    28
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    122
  • 氢给体数:
    0
  • 氢受体数:
    9

反应信息

  • 作为反应物:
    描述:
    tetraethyl 9-oxoheptadecane-1,8,10,17-tetracarboxylate盐酸溶剂黄146 作用下, 以 为溶剂, 反应 18.0h, 以1.74g的产率得到10-氧壬二酸
    参考文献:
    名称:
    [EN] BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    [FR] LIPIDES BIODÉGRADABLES RAMIFIÉS À TERMINAISONS ALKYLE ET CYCLOALKYLE DESTINÉS À L'ADMINISTRATION D'AGENTS ACTIFS
    摘要:
    本发明涉及具有一个或多个生物可降解基团的阳离子脂质的化学式(I),所述生物可降解基团位于阳离子脂质的脂质部分(例如,疏水链)中。这些阳离子脂质可以被纳入脂质粒子中,用于传递活性剂,例如核酸。该发明还涉及包括中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选地固醇的脂质粒子。脂质粒子还可以进一步包括治疗剂,例如核酸。
    公开号:
    WO2013086322A1
  • 作为产物:
    描述:
    8-溴辛酸乙酯1,3-丙酮二羧酸二乙酯sodium ethanolate 作用下, 以 乙醇 为溶剂, 反应 18.0h, 以11.44g的产率得到tetraethyl 9-oxoheptadecane-1,8,10,17-tetracarboxylate
    参考文献:
    名称:
    [EN] BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    [FR] LIPIDES BIODÉGRADABLES RAMIFIÉS À TERMINAISONS ALKYLE ET CYCLOALKYLE DESTINÉS À L'ADMINISTRATION D'AGENTS ACTIFS
    摘要:
    本发明涉及具有一个或多个生物可降解基团的阳离子脂质的化学式(I),所述生物可降解基团位于阳离子脂质的脂质部分(例如,疏水链)中。这些阳离子脂质可以被纳入脂质粒子中,用于传递活性剂,例如核酸。该发明还涉及包括中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选地固醇的脂质粒子。脂质粒子还可以进一步包括治疗剂,例如核酸。
    公开号:
    WO2013086322A1
点击查看最新优质反应信息

文献信息

  • [EN] LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF<br/>[FR] COMPOSÉS LIPIDIQUES COMPRENANT AU MOINS UN RADICAL TERMINAL DE FORMULE -NH-CX-A OU -NH-CX-NH-A, COMPOSITIONS LES CONTENANT ET LEURS UTILISATIONS
    申请人:SANOFI PASTEUR
    公开号:WO2022013443A1
    公开(公告)日:2022-01-20
    The disclosure relates to novel lipidic compounds, lipid nanoparticles (LNPs) containing thereof, and the use of the lipidic compounds or the LNPs for the delivery of nucleic acid. The lipidic compounds as disclosed herein comprise at least one terminal radical of formula (I): *-NH-CX-(NH)n-A (I) wherein: - *- represents a single bond linking said radical of formula (I), directly or not, to to one C10 to C55 lipophilic or hydrophobic tail-group; - n is 0 or 1; - X is an oxygen or sulfur atom, and - A represents an optionally substituted 5- or 6-membered unsaturated heterocyclic radical or 5- or 6-membered heteroaromatic ring radical, both containing at least one nitrogen atom; or one of the pharmaceutically acceptable salts of said radical of formula (I); and with said compound that is in all the possible racemic, enantiomeric and diastereoisomeric isomer forms.
    该披露涉及新型脂质化合物,含有该脂质化合物的脂质纳米颗粒(LNPs),以及利用该脂质化合物或LNPs用于传递核酸。所述的脂质化合物至少包括一个式(I)的末端基团:*-NH-CX-(NH)n-A(I)其中:- *-代表连接所述式(I)的基团的单键,直接或间接地,连接到一个C10至C55的亲脂性或疏性尾基团;- n为0或1;- X为氧或原子,- A代表一个可选择地取代的含有至少一个氮原子的5-或6-成员不饱和杂环基团或5-或6-成员杂芳环基团;或所述的式(I)基团的药学上可接受的盐之一;以及与所述化合物一起,以所有可能的外消旋、对映异构体和顺反异构体形式存在。
  • LIPID COMPOSITION
    申请人:FUJIFILM Corporation
    公开号:US20220096381A1
    公开(公告)日:2022-03-31
    An object of the present invention is to provide a lipid composition making it possible to achieve excellent delivery of nucleic acids. According to the present invention, there is provided a lipid composition containing a lipid represented by Formula (1) or a salt thereof, a nonionic lipid, a lipid having a nonionic hydrophilic polymer structure, and a nucleic acid, in which the lipid composition contains or does not contain a zwitterionic lipid, and in a case where (A) represents a molar ratio in percentage of the lipid represented by Formula (1) or a salt thereof to total lipids constituting the lipid composition and (B) represents a molar ratio in percentage of the zwitterionic lipid to total lipids constituting the lipid composition, (A) and (B) satisfy 40<(A)−(B)≤90. In the formula, X represents —NR 1 — or —O—, R 1 represents a hydrogen atom, a hydrocarbon group, or the like, R 2 and R 3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R 4 and R 5 , R 10 and R 5 , R 5 and R 12 , R 4 and R 6 , R 5 and R 6 , R 6 and R 7 , R 6 and R 10 , R 12 and R 7 , and R 7 and R 8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a+b is 1 or more, and c+d is 1 or more.
    本发明的目的是提供一种脂质组合物,使得核酸的传递能够实现优异。根据本发明,提供一种脂质组合物,其中包含式(1)或其盐所代表的脂质、非离子脂质、具有非离子亲性聚合物结构的脂质和核酸,所述脂质组合物包含或不包含一个带电离子脂质,且当(A)代表式组成脂质组合物中式(1)或其盐所代表的脂质的摩尔比例百分比,(B)代表式组成脂质组合物中带电离子脂质的摩尔比例百分比时,(A)和(B)满足40 < (A) - (B) ≤ 90。在式中,X代表—NR1—或—O—,R1代表氢原子、烃基或类似物,R2和R3各自独立地代表氢原子、烃基或类似物,R4、R5、R6、R7、R8、R9、R10、R11和R12各自独立地代表氢原子或烷基,R4和R5、R10和R5、R5和R12、R4和R6、R5和R6、R6和R7、R6和R10、R12和R7以及R7和R8中的任意一个或多个成对的基团可以连接在一起形成一个含氧原子的4-7环,a、b、c和d各自独立地代表0到3的整数,a+b≥1,c+d≥1。
  • Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents
    申请人:ALNYLAM PHARMACEUTICALS, INC.
    公开号:US20150005363A1
    公开(公告)日:2015-01-01
    The present invention relates to a cationic lipid of formula (I) having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    本发明涉及一种具有公式(I)的阳离子脂质,其中在脂质部分(例如,疏链)中具有一个或多个可生物降解的基团。这些阳离子脂质可以被纳入到脂质粒中,以传递活性剂,例如核酸。本发明还涉及包括中性脂质、能够减少聚集的脂质、本发明中的阳离子脂质以及可选的固醇的脂质粒。该脂质粒还可以包括治疗剂,例如核酸。
  • COMPOUND, SALT THEREOF AND LIPID PARTICLES
    申请人:FUJIFILM Corporation
    公开号:EP3805198A1
    公开(公告)日:2021-04-14
    An object of the present invention is to provide a compound or a salt thereof constituting lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids. According to an aspect of the present invention, a compound represented by Formula (1) or a salt thereof is provided. In the formula, X represents -NR1- or -O-, R1 represents a hydrogen atom, a hydrocarbon group, or the like, R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R4, R5, R6, R7, R8, R9, R10, R11, and R12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R4 and R5, R10 and R5, R5 and R12, R4 and R6, R5 and R6, R6 and R7, R6 and R10, R12 and R7, and R7 and R8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a + b is equal to or greater than 1, and c + d is equal to or greater than 1.
    本发明的目的是提供一种化合物或其盐类构成的脂质微粒,该脂质微粒可实现较高的核酸包封率和核酸的良好递送,并提供可实现较高的核酸包封率和核酸的良好递送的脂质微粒。根据本发明的一个方面,提供了一种由式(1)代表的化合物或其盐。 式中,X代表-NR1-或-O-,R1代表氢原子、烃基或类似物,R2和R3各自独立地代表氢原子、烃基或类似物,R4、R5、R6、R7、R8、R9、R10、R11和R12各自独立地代表氢原子或烷基、R4和R5之间任意一对或多对的基团、R10 和 R5、R5 和 R12、R4 和 R6、R5 和 R6、R6 和 R7、R6 和 R10、R12 和 R7 以及 R7 和 R8 中的任意一对或多对基团可彼此相连,形成可包含 O 原子的 4 至 7 元环,a、b、c 和 d 各自独立地代表 0 至 3 的整数,a + b 等于或大于 1,c + d 等于或大于 1。
  • BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    申请人:Alnylam Pharmaceuticals, Inc.
    公开号:EP2788316B1
    公开(公告)日:2019-04-24
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸